At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizerprogulf.com
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com
AbbVie was founded in 2013 when we became a separate company from Abbott. Our name represents a proud connection to that legacy
AbbVie formed a new kind of enterprise – a biopharmaceutical company – with the stability, global scale, resources and commercial capabilities of a pharmaceutical company and the focus and culture of a biotech.
Since the beginning, our mission hasn’t wavered. Our combination of focused innovation and commercial scale brings differentiated products to market that benefit patients, customers and health care providers. www.abbvie.com
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. www.merckgroup.com
Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: “Take what you find here and make it better and better.”
More than 140 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live. www.lilly.com
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer’s disease.
The company routinely posts information that may be important to investors on its website at www.biogen-gulf.com. To learn more, please visit www.biogen-gulf.com and follow Biogen on social media – youtube, facebook, linkedin, twitter.
Lundbeck is a Global Pharmaceutical Company Specialized in Brain Diseases, We are tirelessly dedicated to restoring brain health, so every person can be their best. To fulfill this purpose, Lundbeck is engaged in the research, development, manufacturing, and commercialization of pharmaceuticals across the world. For more than 70 years, Lundbeck has been at the forefront of neuroscience research. www.lundbeck.com
NewBridge Pharmaceuticals, headquartered in Dubai – U.A.E., is a regional specialty pharmaceutical company focused on in-licensing and commercializing USFDA and/or EMA approved innovative therapeutics that address unmet medical needs in the Middle East and Africa Region.
NewBridge’s current focus is to bring innovation to enhance the patient’s journey in the field of oncology, immunology, neuroscience, gastrointestinal and rare diseases. www.nbpharma.com
Genpharm is a private pharmaceutical company founded in 2012 and based in the Dubai Science Park (DSP), U.A.E. We are the leading partner for Rare Diseases and Speciality companies for the Middle East and Turkey. We provide our partners with fast track market access and sustainable go-to market and tailored commercial strategies. Our core activities are focused on disease awareness, early patient diagnosis, as well as, scientific, medical and CME events. We work closely with the key scientific societies and the key stakeholders. We are the first organization to successfully introduce gene and cell therapy in the Region. Our current partners are Novartis Gene Therapies, Orchard Therapeutics, PTC, Amicus, Sarepta, Ultragenyx, Albireo, Quoin, Argenx and others. We operate through the highest ethical standards and have been audited by all of our partners for Compliance, Quality and PV. www.genpharmservices.com